R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Mutations affecting codon 132 of the enzyme cytosolic isocitrate dehydrogenase 1 (IDH-1) have been found in 68%–86% of World Health Organization (WHO) grade II and III astrocytic and oligodendroglial tumors in adults, as well as in the majority of WHO grade IV secondary glioblastomas that evolved from these lower-grade tumors [3,4,8]. IDH-1 is localized in the cytoplasm and peroxisomes and serves as a major source for cytosolic nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is necessary for the regeneration of reduced glutathione, which functions as the main antioxidant in mammalian cells. Glioma-specific mutations in IDH-1 usually affect the amino acid arginine at position 132 of the amino acid sequence [3,5,8], resulting in a substitution of histidine for arginine. This mutation only affects one allele and results in a decrease in IDH-1 activity. Inactivation of IDH-1 has been linked to elevated oxidative stress, which has been hypothesized to confer an increased sensitivity to chemotherapy and radiotherapy [5]. A recent report suggests that the R132H mutation in IDH-1 may lead to accumulation of hypoxia-inducible factor 1 alpha (HIF-1α) in glioma cells [10]. Given that the activation of the HIF-1α pathway is associated with malignant progression and unfavorable outcomes in various tumor types [6], overexpression of HIF-1α as a result of the R132H IDH-1 mutation has been hypothesized to act as a driver for malignant transformation in gliomas. To test the hypothesis that expression of R132H-mutated IDH-1 specifically leads to overexpression of HIF-1α in human gliomas in vivo, we examined a large panel of glial tumors for association between R132H-mutated IDH-1 and HIF-1α expression using immunohistochemistry. We analyzed a total of 120 archived formalin-fixed paraffin embedded glioma specimens from 115 patients. Immunohistochemistry for R132H-mutated IDH-1 was performed using mouse anti-human isocitrate dehydrogenase-1 mutation (R132H) antibody, clone H09, as previously described [1]. To determine the spatial localization of HIF-1α in relation to R132H-mutated IDH-1 tumor cells, immunohistochemistry for HIF-1α was performed in adjacent sections as previously described [9]. As a control, we also performed HIF-1α immunostaining on five (including one pediatric) of the 37 IDH-1 negative primary GBMs. The patients’ clinical demographics and histology for the 115 tumor samples are shown in Table 1. Patient age at first surgery ranged from 1 to 80 years, with a median age of 40 years. There were 58 males and 57 females. Immunohistochemical evidence of tumor cells with R132H-mutated IDH-1 was present in 25/138 (18.1%) of patients. In patients positive for R132H-mutated IDH-1, ages ranged from 18 to 64 years of age with a mean age of 46 years. The large number of pediatric patients studied, i.e. 41/115 (35.7%) resulted in a younger median age (40 years) in our overall patient cohort compared to the adult series. However, all of the patients positive for R132H-mutated IDH-1 were adult patients (age ≥18 years) and therefore, the median age of the positive patients was higher (46 years) than the overall median age. The lower rate of IDH-1 mutations in secondary glioblastomas in our series is likely a result of the small number of patients with secondary glioblastomas in our cohort. Table 1 Clinical characteristics of all study patients and summary of immunohistochemistry results for R132H-mutated IDH-1 and HIF-1α All tumors positive for R132H-mutated IDH-1 (n=25) were carefully evaluated for HIF-1α expression in serial sections. We found that a subset of cells expressing R132H-mutant IDH-1 also expressed HIF-1α. In specimens that showed necrosis, HIF-1α up-regulation was evident in cells adjacent to areas of necrosis (Figure 1), as previously reported [9] although in several tumors HIF-1α expression was not associated with necrotic zones. HIF-1α, however, was not overexpressed in other areas of the tumors, including those with strong immunoreactivity for R132H-mutated IDH-1. HIF-1α was seen in perinecrotic tumor cells in 8 cases, in groups of cells in 5 cases, and in both perinecrotic and groups of cells in 1 case. Therefore, no relation between the expression of R132H-mutated IDH-1 and HIF-1α was evident. The five IDH-1 negative GBMs that were also stained for HIF-1α showed a pattern of HIF-1α immunoreactivity similar to the R132H-mutated GBMs. Figure 1 Expression of R132H-mutated IDH-1 and HIF-1α in a secondary glioblastoma (WHO Grade IV/IV) (a,b,c) and in anaplastic mixed glioma (oligodendroglioma/astrocytoma) (WHO grade III/III) (d,e,f) Our findings indicate that although HIF-1α is upregulated in a subset of gliomas in vivo, activation of the HIF-1α pathway is not primarily regulated by R132H-mutated IDH-1, but more likely via other established mechanisms such as hypoxia and/or growth-factor dependent transcriptional regulation [7]. We feel that the picture of glioma tumor progression in regards to the R132H IDH-1 mutation is more complex than the current literature suggests, and is not entirely explained by the previously reported reduced levels of alpha-ketoglutarate that regulate HIF-1α. Rather than HIF-1α activation, our findings support alternate mechanisms that drive the progression of IDH-1 mutant gliomas, such as the recently reported excess accumulation of 2HG [2].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 1×
“[6, 7].”
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“A recent report suggests that the R132H mutation in IDH-1 may lead to accumulation of hypoxia-inducible factor 1 alpha (HIF-1a) in glioma cells [10].”
Background
Cited by
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
“The weight of the evidence now suggests that regulation of HIF-1 stability through decreased PHD2 activity is not the primary effect of IDH mutations (Chowdhury et al., 2011; Dang et al., 2009; Jin et al., 2011; Mardis et al., 2009; Metellus et al., 2011; Williams et al., 2011).”
BackgroundMetabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
Mechanisms of Glioma-Associated Neovascularization
Hardee, M. E., & Zagzag, D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.06.030 · Cited by 475
Self-citation
Metadata
- Authors
- Williams, S. C., Karajannis, M. A., Chiriboga, L., Golfinos, J. G., von Deimling, A., & Zagzag, D.
- Venue
- Acta Neuropathologica
- Published
- 2010-12-24
- Volume
- 121
- Issue
- 2
- Pages
- 279-281
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2049250159
- Cited by
- 70
- References
- 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. https://app.cochat.ai/papers/10.1007/s00401-010-0790-y
- The paper
- Williams, S. C., Karajannis, M. A., Chiriboga, L., Golfinos, J. G., von Deimling, A., & Zagzag, D. (2011). R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathologica. https://doi.org/10.1007/s00401-010-0790-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.